Harvoni (ledipasvir/sofosbuvir)
contains a HCV NS5A inhibitor
(ledipasvir) and a nucleotide
inhibitor of HCV NS5B
RNA‑dependent RNA polymerase
(sofosbuvir). Harvoni is indicated
for the treatment of chronic
hepatitis C (CHC) genotype 1
infection in adults. Harvoni should
not be administered concurrently
with other medicinal products
containing any of the same active
components. Harvoni is available
as a fixed dose combination tablet
containing 90 mg of ledipasvir and
400 mg of sofosbuvir. Harvoni is
available as a bottle of 28 tablets.The above article was sent to subscribers in Pharmacy Daily's issue from 06 Jul 15 To see the full newsletter, see the embedded issue below or CLICK HERE to download Pharmacy Daily from 06 Jul 15
THE Pharmaceutical Society of Australia (PSA) awarded Brooke Shelly the prestigious 2024 PSA MIMS Credentialed Pharmacist of the Year award last Fri at the Credentialed Pharmacist Conference (CPC24) (PD breaking news).
THE Pharmaceutical Society of Australia (PSA) has unveiled a comprehensive membership package designed to provide robust support for credentialed pharmacists throughout their professional journey.
MEDICAL research produces better outcomes when people with lived experience are involved in the process, according to Breast Cancer Network Australia (BCNA).
FREE Pharmacy Daily subscription - never miss another story!
to top
Subscribe to Pharmacy Daily
Pharmacy Daily subscription confirmation
Thank you for signing up! Check your email inbox – you should shortly receive a message with a link which must be clicked to confirm your subscription.
Once you’ve done that you will begin receiving Pharmacy Daily as soon as the next issue is published.